Trial Profile
A Dose Escalation Evaluation of Safety and Tolerability of Adrecizumab - a Humanized Monoclonal Antibody Against Adrenomedullin (ADM) in Patients With Acute Heart Failure Requiring Hospitalization
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Enibarcimab (Primary)
- Indications Acute heart failure; Decompensated heart failure
- Focus Adverse reactions; Proof of concept
- Acronyms ADESTE
- 08 Mar 2021 Planned End Date changed from 31 Dec 2020 to 31 Mar 2022.
- 08 Mar 2021 Planned primary completion date changed from 30 Jun 2020 to 31 Dec 2021.
- 31 Jan 2020 Status changed from planning to recruiting.